Main image Main image

Cend Therapeutics in the News

November 20, 2020

To honor the Pancreatic Cancer Awareness Day (today) and Pancreatic Cancer Awareness Month (November) we are raising awareness about the symptoms and risks of this devastating disease and the urgent need for earlier detection.

 

The results of our first clinical trial testing CEND-1 in pancreatic cancer patients were published at the annual European cancer meeting ESMO 2020 and Annals of Oncology. We are now preparing to test CEND-1 in multi-center randomized clinical trials in pancreatic cancer patients and expand into additional indications in our effort to help patients with hard-to-treat solid tumors.

September 25, 2020

San Diego, September 21, 2020 – Cend Therapeutics, Inc., a clinical-stage biotech company, announced today that it has acquired Impilo Therapeutics, Inc. The combination expands Cend’s drug delivery capabilities to create a unique platform for targeted tissue penetrating delivery of nucleic acid-based medicines to solid tumor cancers.

 

While antisense and siRNA medicines have reached market for a range of metabolic, neurological and neuro-muscular conditions, none have reached market for anticancer applications. “By combining Impilo with Cend our objective is to address delivery issues that have limited the ability of nucleic acid-based medicines to benefit cancer patients,” commented David Slack, CEO of Cend.

 

“Cend’s lead asset, CEND-1, has generated encouraging clinical data showing the ability to enhance delivery of standard-of-care chemotherapy for pancreatic cancer patients, and the Company has generated similarly encouraging preclinical results for a variety of therapeutic modalities,” commented Sangeeta Bhatia, MD, PhD, scientific co-founder of Impilo and Director of MIT’s Center for Cancer Nanomedicine.

 

“With the combination of Cend and Impilo technologies, we have demonstrated unique abilities to deliver antisense, siRNA, microRNA, and immunostimulatory oligonucleotides selectively to

solid tumor cancers and certain immune cells,” commented Frank Slack, PhD, scientific cofounder of Impilo and Director of Harvard’s Initiative for RNA Medicine.

 

“The scientific founders of Cend and Impilo have collaborated for many years and generated significant publications” commented Cend Executive Chairman, Erkki Ruoslahti. “Cend will

continue to work closely with Impilo’s founders as part of our extended team.”

 

Via acquisition of Impilo’s assets, the CendR PlatformÔ combines Cend’s clinical-stage targeted tumor penetrating peptide, CEND-1, with additional targeting capabilities. It also brings

nanoparticle technologies, including fusogenic nanoparticles that can deliver high payloads of nucleic acid-based drugs directly into the cytosol compartment of cells.

Financial details of the transaction have not been disclosed. Accompanying the acquisition, Sangeeta Bhatia and Frank Slack will join Erkki Ruoslahti, MD, PhD; Tambet Teesalu, PhD; and

Kazuki Sugahara, MD on Cend’s Scientific Advisory Board. Impilo scientific co-founder and Distinguished Professor at UC San Diego, Michael Sailor, PhD will join Cend’s Board of Directors.

About Cend Therapeutics

 

September 21, 2020